Welcome to our dedicated page for Glaukos Corporation news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos Corporation stock.
Glaukos Corporation (NYSE: GKOS) is a prominent ophthalmic medical technology company specializing in breakthrough products and procedures aimed at transforming the treatment of glaucoma. As one of the leading causes of blindness globally, glaucoma demands innovative solutions, and Glaukos has pioneered micro-invasive glaucoma surgery (MIGS) to revolutionize traditional management paradigms.
The company's flagship product, the iStent Trabecular Micro-Bypass Stent, launched in the United States in 2012, is celebrated for being the smallest medical device ever approved by the FDA, measuring a mere 1.0 mm long and 0.33 mm wide. This device is designed to reduce intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma when used in conjunction with cataract surgery.
Building on the success of the iStent, Glaukos is developing a comprehensive and proprietary portfolio of injectable micro-scale therapies targeting the entire spectrum of glaucoma disease states and progression. The pipeline includes the iStent SA Trabecular Micro-Bypass System, a two-stent product with a different auto-injection inserter for standalone procedures.
In June 2015, Glaukos successfully completed its initial public offering, and its shares are now publicly traded on the New York Stock Exchange. The company continues to innovate and expand its product offerings, maintaining its position as a leader in the ophthalmic medical technology field.
- Recent achievements include the expansion of their product pipeline and the ongoing development of next-generation MIGS devices.
- Current projects focus on enhancing the efficacy and accessibility of glaucoma treatments worldwide.
- Partnerships with leading ophthalmic institutions and research organizations fuel Glaukos' mission to improve patient outcomes.
Glaukos Corporation remains committed to transforming glaucoma treatment through technological innovation and strategic growth.
Glaukos Corporation (NYSE: GKOS) reported Q1 2022 financial results, with net sales of $67.7 million, slightly down from $68.0 million in Q1 2021. Glaucoma sales accounted for $51.5 million, while Corneal Health contributed $16.1 million. The gross margin was approximately 75%, and operating expenses increased to $40.8 million. The company reported a net income of $5.4 million ($0.11 per diluted share), compared to a net loss of $16.5 million in the same period last year. Glaukos updated its 2022 net sales guidance to $270 million - $275 million.
Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, will present its innovative products at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting from April 22-26, 2022, in Washington, D.C. Glaukos is sponsoring an educational symposium titled “Expanding Your Treatment Algorithm: New, Innovative Product Portfolio from Glaukos” on April 22 at 5:30 PM, featuring notable experts. Key presentations will include findings on the Trabecular Micro-Bypass Stent and other advancements in glaucoma and corneal health therapies, enhancing their market presence and potential future growth.
Glaukos Corporation (NYSE: GKOS) will announce its first quarter 2022 financial results after market close on May 4, 2022. A conference call will follow at 1:30 p.m. PT (4:30 p.m. ET) to discuss the findings. Investors can access the live webcast through the company's website and call in using specific phone numbers for U.S. and international participants. Glaukos specializes in innovative treatments for glaucoma, corneal disorders, and retinal diseases, having introduced Micro-Invasive Glaucoma Surgery (MIGS) in 2012.
Glaukos Corporation (NYSE: GKOS) has announced the initiation of a Phase 2 clinical program for its third-generation iLink™ therapy aimed at treating keratoconus. This innovative therapy utilizes a proprietary system to deliver ultraviolet light for corneal cross-linking, enhancing the strength and shape of the cornea. The Phase 2 study will involve two multi-center, randomized, controlled trials to assess customized versus non-customized treatment patterns and a new bio-activation system. Patient enrollment will occur across the United States, Europe, South America, and Asia, with a follow-up period of six months.
Glaukos Corporation (GKOS) reported its Q4 2021 net sales at $73.2 million, consistent with Q4 2020. Glaucoma and Corneal Health net sales were $57.1 million and $16.2 million, respectively. The gross margin improved to 77% from 73% a year earlier. However, the company faced a net loss of $21.9 million, or ($0.47) per diluted share, worsened from a net loss of $10.6 million in Q4 2020. For the full year, net sales increased by 31% to $294.0 million. The company projects 2022 net sales between $265 million and $275 million.
Glaukos Corporation (NYSE: GKOS) has announced key executive leadership changes effective April 1, 2022, to drive future growth. Joseph Gilliam becomes President and COO, previously CFO since May 2017. Chris Calcaterra transitions to Executive VP, Global Commercial Operations, after serving as COO since February 2017. Alex Thurman is promoted to CFO, having been VP of Finance. Tomas Navratil, Ph.D., takes on the role of Chief Development Officer, focusing on R&D. These promotions aim to align leadership with strategic objectives for transforming chronic eye disease treatments.
Glaukos Corporation (NYSE: GKOS) will announce its fourth quarter and full year 2021 financial results post-market on February 22, 2022. A conference call is scheduled for 1:30 p.m. PST (4:30 p.m. EST) the same day to discuss these results. Investors can access the live webcast via the company’s website. Glaukos specializes in innovative therapies for glaucoma and related ophthalmic disorders, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) and launched multiple devices since 2012.
Glaukos Corporation (NYSE:GKOS) announced positive outcomes from its Phase 2b clinical trial of the iDose TR implant for glaucoma treatment, showing that approximately 70% of subjects maintained controlled intraocular pressure with fewer topical medications over 36 months. The trial demonstrated an average IOP reduction of 8.3 mmHg and a favorable safety profile, with no significant adverse effects reported. Following these promising results, Glaukos is preparing for a Phase 3 trial, with NDA submission targeted for 2022 and potential FDA approval in 2023.
Glaukos Corporation (NYSE: GKOS) has commenced a Phase 2 clinical trial of GLK-301, targeting Dry Eye Disease (DED). This investigational drug, using Glaukos' innovative iLution platform, is formulated as a cream applied to the eyelids for transdermal delivery of pilocarpine. The trial will assess safety and efficacy across 200 patients over 28 days, followed by a safety follow-up. This development addresses a significant clinical need in the ophthalmic market, as stated by CEO Thomas Burns, emphasizing the potential of the iLution platform in treating chronic eye diseases.
FAQ
What is the current stock price of Glaukos Corporation (GKOS)?
What is the market cap of Glaukos Corporation (GKOS)?
What is Glaukos Corporation?
What is the iStent Trabecular Micro-Bypass Stent?
When did Glaukos go public?
What is MIGS?
What is the iStent SA?
What recent achievements has Glaukos made?
What is the significance of Glaukos' products?
Who are Glaukos' partners?
What is Glaukos' mission?
How does Glaukos continue to innovate?
